Raw research findings for this medication. Mostly single studies, not curated or confirmed robust.
Vincristine is a vinca alkaloid chemotherapy medicine from the Madagascar periwinkle. It blocks the assembly of microtubules, so dividing cells cannot separate their chromosomes. It is a key part of treatment for acute lymphoblastic leukaemia, lymphomas (in CHOP) and many childhood cancers. Nerve damage (neuropathy) is its main dose-limiting side effect. It is sold as Oncovin, among other names.
Vincristine is broken down mainly by CYP3A5 and CYP3A4 and pumped out of cells by ABCB1. Children of African ancestry, who more often carry working CYP3A5 copies, clear it faster and in studies had less nerve damage. A genome-wide study in children with leukaemia linked a CEP72 variant to more neuropathy. The findings come from a few studies, and there is no CPIC or DPWG guideline.
Every published finding on gene variants and Vincristine. Upload your DNA file to see which of these rows apply to you.
PharmGKB weighs all studies of a variant and rates how strong the evidence is, from 1A (strongest) to 4.
CEP72 rs924607: Level 3. Toxicity: Peripheral Nervous System Diseases. 7.
ABCB1 rs1128503: Level 3. Efficacy: Osteosarcoma. 2.
ABCB1 rs4148737: Level 3. Efficacy: Osteosarcoma. 2.
PNPLA3 rs738409: Level 3. Toxicity: Acute lymphoblastic leukemia. 2.
Studies of how quickly the body processes this medication.
Studies of how well it worked in people carrying a variant.
Studies of side effects in people carrying a variant.
Studies that do not fall into the groups above.
rs1247117: Allele G is associated with increased resistance to vincristine as compared to allele A.
Study findings and evidence levels: PharmGKB (CC BY-SA 4.0). Guidelines: CPIC and DPWG, as bundled in PharmCAT. Most studies were done mainly in people of European ancestry.
More drugs from the same category
Not a prescribing recommendation. This page is educational information about pharmacogenomic research and clinical guidelines - it is not medical or dosing advice, and not a prediction of how any medication will work for you. Never start, stop, or change a medication or dose based on it; talk to your doctor or pharmacist, who can order clinical-grade testing if appropriate.
Content updated September 2026.
ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.
Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026
Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com